Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 282

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 282
---
    )

    (56,541
    )

    Net cash used in operating activities

    (22,514,121
    )

    (14,227,428
    )

    Cash flows from investing activities:

    Purchases of property and equipment

    (6,202,600
    )

    (261,617
    )

    Proceeds for sale or maturities of short-term investments

    10,000,000

    —

    Net cash provided by (used in) investing activities

    3,797,400

    (261,617
    )

    Cash flows from financing activities:

    Proceeds from issuance of common stock

    23,739

    6,462,834

    Proceeds from issuance of debt

    —

    6,905,000

    Proceeds from common stock warrants

    —

    2,958,125

    Issuance costs for common stock and warrants

    —

    (638,045
    )

    Debt repayment

    (38,273
    )

    (119,398
    )

    Net cash (used in) provided by financing activities

    (14,534
    )

    15,568,516

    Net (decrease) increase in cash and cash equivalents

    (18,731,255
    )

    1,079,471

    Cash and cash equivalents at the beginning of the period

    22,326,356

    3,595,101

    Cash and cash equivalents at the end of the period
     
    $
    3,595,101

    $
    4,674,572

    Supplemental disclosure of cash flow information:

    Cash paid for interest, net of amounts capitalized
     
    $
    283,042

    $
    569,770

    Noncash operating, investing and financing activities:

    Capital expenditures accrued, but not yet paid
     
    $
    4,240,593

    $
    2,010,478

    Purchases of property and equipment included in accounts payable and other liabilities
     
    $
    —

    $
    829,207

    Reserve for credit losses
     
    $
    5,250,000

    $
    —

The accompanying notes are an integral part of these financial statements. 

102

HCW Biologics Inc. 

Notes to the Financial Statements 

December